Allspring Global Investments Holdings LLC Acquires Shares of 270,924 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Allspring Global Investments Holdings LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 270,924 shares of the biopharmaceutical company's stock, valued at approximately $69,292,000. Allspring Global Investments Holdings LLC owned approximately 0.21% of Alnylam Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ALNY. Brighton Jones LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $243,000. Truist Financial Corp lifted its holdings in shares of Alnylam Pharmaceuticals by 136.6% during the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after purchasing an additional 2,539 shares during the period. IFP Advisors Inc grew its stake in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 47 shares during the last quarter. Amalgamated Bank increased its holdings in Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Amalgamated Bank now owns 8,484 shares of the biopharmaceutical company's stock valued at $1,996,000 after purchasing an additional 205 shares during the period. Finally, Nwam LLC increased its holdings in Alnylam Pharmaceuticals by 5.8% in the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock valued at $213,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the transaction, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

ALNY has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Bank of America increased their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Finally, Citigroup boosted their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $340.00.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $7.64 during trading on Wednesday, reaching $329.70. 766,275 shares of the company traded hands, compared to its average volume of 858,926. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $339.59. The stock has a market capitalization of $42.99 billion, a PE ratio of -157.75 and a beta of 0.23. The firm has a 50 day simple moving average of $289.81 and a 200-day simple moving average of $264.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same period in the prior year, the company posted ($0.16) EPS. The firm's revenue was up 20.2% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.